Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody
Paul E. Monahan(CSL (United States)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai)
Cited by 12
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587